Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 MAD Study of REL-1017 (d-Methadone) in Healthy Subjects
NCT03638869Phase 1Completed
- Sponsor
- Relmada Therapeutics, Inc.
- Start
- Aug 2015
- Primary completion
- Nov 2015
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of esmethadone in neuropathic pain and major depressive disorder (MDD) (4 arms), sponsored by Relmada Therapeutics, Inc. Primary endpoint: Adverse Events at Day 18. Started Aug 2015; status: completed.
02
Drugs
esmethadone
03
Conditions
neuropathic painmajor depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03638869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03638869.